Larry Zhang Net Worth

The estimated Net Worth of Larry Zhang is at least $152 Thousand dollars as of 22 July 2020. Larry Zhang owns over 20,153 units of CASI Pharmaceuticals Inc stock worth over $152,155 and over the last 5 years Larry sold CASI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Larry Zhang CASI stock SEC Form 4 insiders trading

Larry has made over 1 trades of the CASI Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Larry bought 20,153 units of CASI stock worth $38,291 on 22 July 2020.

The largest trade Larry's ever made was buying 20,153 units of CASI Pharmaceuticals Inc stock on 22 July 2020 worth over $38,291. On average, Larry trades about 6,718 units every 0 days since 2019. As of 22 July 2020 Larry still owns at least 20,153 units of CASI Pharmaceuticals Inc stock.

You can see the complete history of Larry Zhang stock trades at the bottom of the page.

What's Larry Zhang's mailing address?

Larry's mailing address filed with the SEC is CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE, MD, 20850.

Insiders trading at CASI Pharmaceuticals Inc

Over the last 12 years, insiders at CASI Pharmaceuticals Inc have traded over $0 worth of CASI Pharmaceuticals Inc stock and bought 30,834,178 units worth $51,898,666 . The most active insiders traders include Wei Wu He, Rajesh C Md Shrotriya, and Pharmaceuticals Inc Spectru.... On average, CASI Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $6,141,555. The most recent stock trade was executed by James Huang on 6 September 2022, trading 55,573 units of CASI stock currently worth $229,516.

What does CASI Pharmaceuticals Inc do?

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.

Complete history of Larry Zhang stock trades at CASI Pharmaceuticals Inc

CASI Pharmaceuticals Inc executives and stock owners

CASI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Wei-Wu He,
  Executive Chairman of the Board, Chief Executive Officer
• Alexander Zukiwski,
  Chief Medical Officer
• Wei Zhang,
  President, President of CASI China, Interim Principal Financial Officer
• Dr. Wei-Wu He Ph.D.,
  Chairman & CEO
• Dr. Wei Zhang Ph.D.,
  Pres & Principal Financial Officer
• Dr. Alexander A. Zukiwski M.D.,
  Exec. VP & Chief Medical Officer
• James Huang,
  Independent Director
• Y. Alexander Wu,
  Independent Director
• Franklin Salisbury,
  Independent Director
• Quan Zhou,
  Independent Director
• Rajesh Shrotriya,
  Independent Director
• Amanda Cui,
  VP & Global Controller
• Dr. James E. Goldschmidt Ph.D.,
  Chief Bus. Devel. Officer
• Sara B. Capitelli CPA,
  VP of Fin.
• Byte Ltdsnow Moon Ltdtianji...,
  
• Ken Ren,
  CEO and Director
• Pharmaceuticals Inc Spectru...,
  
• Alex Wu,
  Director
• Tak W. Mak,
  Director
• China Growth Fund Iii L.P.I...,
  
• Strategy Holding Ltd Wealth,
  10% owner
• Sara B Capitelli,
  VP, Finance & PAO
• George Chi,
  Chief Financial Officer
• Cynthia W. Hu,
  See Remarks
• Byte Ltdsnow Moon Ltdtianji...,
  
• Ken Keyong Ren,
  Chief Executive Officer
• Larry Zhang,
  President
• Weihao Xu,
  Chief Financial Officer